Sort   by:  
 Page size 
GenomicsMEK1/2 inhibitors unlock the constrained interferon response in macrophages through IRF1 signaling
MEK1/2 inhibitors unlock the constrained interferon response in macrophages through IRF1 signaling
PRJNA508969 | ENA
MetabolomicsDissection of two routes to naïve pluripotency using different kinase inhibitors
Embryonic stem cells (ESCs) can be maintained in the naïve state through inhibition of Mek1/2 and Gsk3 (2i). A relevant effect of 2i is the inhibition of Cdk8/19, which are negative regulators of the Mediator complex, responsible for the activity of enhancers. Inhibition of Cdk8/19 (Cdk8/19i) stimul...
2021-02-10 | MTBLS301 | MetaboLights
GenomicsTranscriptome analysis of cells after SARS-CoV-2 infection and treatment with MEK1/2-inhibitor Zapnometinib.
Transcriptome analysis of cells after SARS-CoV-2 infection and treatment with MEK1/2-inhibitor Zapnometinib.
PRJNA1293367 | ENA
TranscriptomicsGene expression changes in primary Sertoli cells treated with MEK1/2 inhibitor
To investigate the gene expression regualted by MEK1/2-ERK1/2 signaling in Sertoli cells, we cultured primary Seroli cells and treated bFGF and PD0325901, which are activator and inhibitor of the signaling, respectively. Isolated primary Sertoli cells were incubated with 20ng bFGF, 10uM PD0325901 o...
ORGANISM(S): Mus musculus 
2014-02-01 | E-GEOD-41645 | biostudies-arrayexpress
TranscriptomicsExpression Data from 22 human pancreatic cancer cell lines grown in triplicates +/- MEK inhibitor CI-1040
Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. We used microarrays to find gene expression patterns associated with drug response and also identified genes regulated by the MAP kinase pathway 22 pancreatic cell l...
ORGANISM(S): Homo sapiens 
2013-04-04 | E-GEOD-45757 | biostudies-arrayexpress
TranscriptomicsMKK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 cells.
Though mitogen activated protein kinase kinases (MKK or MEK) 1 and 2 are widely assumed to be functionally redundant some reports indicate they possess distinct biologic activities. To test the hypothesis that MEK1 and MEK2 signaling pathways are interchangeable we used two complementary approaches...
ORGANISM(S): Homo sapiens 
2011-06-24 | E-GEOD-23930 | biostudies-arrayexpress
ProteomicsT cell activation decreases microRNA-15a/16 levels as a mechanism to promote MEK1-ERK1/2-Elk1 signaling for optimal proliferative capacity
While microRNAs (miRs) have been extensively studied in the context of malignancy and tumor progression, their functions in regulating T cell activation are less clear. We found reduced levels of miR-15a/16 at 3-18 h post-T cell receptor (TCR) stimulation, suggesting a role in shaping T cell activat...
ORGANISM(S): Mus musculus (Mouse) 
2022-04-04 | PXD030935 | Pride
Microrna (mirna) Cell signaling Mitogen‐activated protein kinase (mapk) Cell growth Cell cycle 
TranscriptomicsExpression Data from 24 orthotopic tumors grown in the pancreas of mice +/- MEK inhibitor PD0325901
Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. We used microarrays to find gene expression patterns associated with drug response and also identified genes regulated by the MAP kinase pathway 6 pancreatic cell li...
ORGANISM(S): Homo sapiens 
2013-04-04 | E-GEOD-45758 | biostudies-arrayexpress
ProteomicsActivation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer
While pancreatic ductal adenocarcinomas (PDAC) are addicted to KRAS-activating mutations, inhibitors of downstream effectors in the KRAS pathway, such as the clinically approved MEK1/2 kinases inhibitor Trametinib, are devoid of significant therapeutic effects. Nevertheless, the extensive rewiring o...
ORGANISM(S): Homo sapiens (Human) 
2024-06-16 | PXD043559 | Pride
Histone post-translational modifications Pancreatic ductal adenocarcinoma 
ProteomicsDifferential patterns of protein expression in monolayer or spheroid melanoma cell models of acquired resistance to BRAF and MEK1/2 inhibitors
Mitogen activated protein kinase (MAPK) inhibitors are important therapies for treating many cancers. However, the development of acquired resistance to most protein kinase inhibitors limit their ability to provide durable responses. Approximately 50% of malignant melanomas contain activating mutati...
ORGANISM(S): Homo sapiens (Human) 
2022-02-17 | PXD026952 | Pride
Monolayer Braf Drug resistance Protein kinases Kinase targeted therapy Selumetinib Spheroids Melanoma Vemurafenib Extracellular-signal regulated kinases 
Sort   by:  
 Page size